Overview

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The primary goal of this study is to examine the triglyceride/HDL ratio and the ischemic EKG changes in patients with schizophrenia, schizoaffective disorder or bipolar disorder.

Phase:

Phase 3

Details

Lead Sponsor:

Northwestern University
Vanderbilt University Medical Center

Collaborator:

National Alliance for Research on Schizophrenia and Depression

Treatments:

Aripiprazole
Ziprasidone